menu
Nearly 70 players engaged in the evaluation of therapeutic candidates based on a number of psychedelic compounds- Roots Analysis'
Nearly 70 players engaged in the evaluation of therapeutic candidates based on a number of psychedelic compounds- Roots Analysis'
Psychedelic substances have been demonstrated to interact with a variety of neurotransmitter pathways, including those involving serotonin, acetylcholine, norepinephrine, and dopamine.

Currently,several stakeholders in the pharmaceutical industry are actively engaged in theefforts to develop leads based on natural and synthetic derivatives ofpsychedelic substances. Further, experts believe that psychedelics, atappropriate doses, can be used to address some of the serious psychologicalimplications associated with the COVID-19 pandemic. 

 

 

To order this 250+page report, which features 120+ figures and 135+ tables, please visit this - https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html

 

 

The overUSD 6.5 billion (by 2030) financial opportunity within the psychedelictherapeutics market has been analyzed across the following segments:

§ Target DiseaseIndication

  • Anxiety and Depression
  • Trauma
  • Pain Disorder
  • Sleep related Disorder

 

§  Originof Psychedelic Substance

  • Natural
  • Synthetic

 

§  Typeof Psychedelic Substance

  • Gamma-hydroxybutyrate
  • Ketamine
  • MDMA
  • Psilocybin

 

§  Routeof Administration

  • Oral
  • Intranasal
  • Sublingual

 

§  KeyGeographies

  • North America
  • Europe
  • Asia-Pacific

 

The GlobalPsychedelic Therapeutics Market, 2020-2030” report features thefollowing companies, which we identified to be key players in this domain:

§  CelonPharma

§  iXBiopharma

§  MAPSPublic Benefit

§  MindMed

§  JanssenPharmaceuticals

§  JazzPharmaceutical

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Market Landscape:Psychedelic Therapeutics

5. Company Profiles

6. Clinical Trial Analysis 

7. Clinical Trial Site Analysis

9. Key Opinion Leader (KOL)Analysis

 

8. Academic Grants Analysis

10. Partnerships andCollaborations

11. Mergers and Acquisitions

12.  Market Forecast andOpportunity Analysis

13. Concluding Remarks

14. Executive Insights

 

15. Appendix 1: Tabulated Data

 

16. Appendix 2: List ofCompanies and Organizations

 

To purchase a copy,please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com